NDAORALCAPSULEPriority Review
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
ANAFRANIL (clomipramine hydrochloride) by Aurobindo Pharma is clinical pharmacology pharmacodynamics clomipramine (cmi) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. First approved in 1989.
Drug data last refreshed 12h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANAFRANIL (clomipramine hydrochloride) is a tricyclic antidepressant that treats obsessive-compulsive disorder by inhibiting serotonin reuptake. It is presumed to influence obsessive and compulsive behaviors through effects on serotonergic neuronal transmission, with its major active metabolite desmethylclomipramine also contributing to clinical effects.
$0.001BPart D
LOE ApproachingDeclining
As a product approaching LOE with minimal Part D spending and low claim volume, brand team headcount is likely contracted and focused on managed decline rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought…
Worked on ANAFRANIL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.